Company Overview

RNA as of 4:00 PM ET on 07/22/14
Day High
Day Low
20 minute delayed data provided by eSignal
Stock price graph

Prosensa is a biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD)Myotonic Dystrophy (DM1) and Huntington's Disease (HD).

Prosensa's portfolio of clinical and pre-clinical RNA-based drug candidates is currently focused on the treatment of DMD, with 6 programs currently in development. Prosensa’s lead candidate for the treatment of DMD, drisapersen, has completed Phase III clinical trials. 

Prosensa commenced operations in 2002 and is located in Leiden, The Netherlands. The company works closely together with academia, patient groups and experts worldwide. 

View all »   RSSRecent Releases

Jul 7, 2014
Prosensa Files F-3 SEC Mixed Shelf Registration For Up To $150 Million

Jun 30, 2014
Prosensa Strengthens its Management Team and Supervisory Board with Key Appointments

View all »Events & Presentations

Aug 20, 2014 at 2:00 PM ET
Prosensa Extraordinary Meeting of Shareholders